SUIT-015: Difference between revisions
From Bioblast
No edit summary |
Beno Marija (talk | contribs) No edit summary ย |
||
(19 intermediate revisions by 8 users not shown) | |||
Line 1: | Line 1: | ||
{{MitoPedia | {{MitoPedia | ||
|abbr= | |abbr=F+G+P+S_OXPHOS+Rot_ET | ||
|description=[[File:1OctM;2D;3G;4P;5S;6U;7Rot-.png| | |description=[[File:1OctM;2D;3G;4P;5S;6U;7Rot-.png|451px]] | ||
|info='''A | |info='''A:ย [[Fatty_acid_oxidation_pathway_control_state|F-pathway]] in [[LEAK respiration#The_LEAK_state |LEAK state]] and [[Oxidative phosphorylation|OXPHOS state]]''' | ||
}} | }} | ||
::: '''[[SUIT protocol pattern]]:''' 1OctM;2D;3G;4P;5S;6U:7Rot- | |||
::: '''[[SUIT protocol pattern]]:''' | ย | ||
SUIT-015 gives information on [[Fatty_acid_oxidation_pathway_control_state|F-pathway]] in [[LEAK respiration#The_LEAK_state |LEAK state]] and [[Oxidative phosphorylation|OXPHOS state]] avoiding FAO overestimation in the presence of [[Anaplerosis|anaplerotic]] pathways. In addition, the pathway control of [[FN]] and [[FNS]] in [[Oxidative phosphorylation|OXPHOS state]] and of [[FNS]] and [[S]] in [[ET capacity| ET state]] can be evaluated. SUIT-015 can be extended with the CIV assay module. | |||
ย | |||
ย | |||
__TOC__ | __TOC__ | ||
ย Communicated by [[Doerrier C]], [[Huete-Ortega M]], | ย Communicated by [[Doerrier C]], [[Huete-Ortega M]], [[Gnaiger E]] (last update 2019-06-05) | ||
ย | |||
== Specific SUIT protocols == | == Specific SUIT protocols == | ||
[[File:1OctM;2D;3G;4P;5S;6U;7Rot | [[File:1OctM;2D;3G;3c;4P;5S;6U;7Rot;8Ama.png|500px]][[File:D042 Traces.png|800px]] | ||
*ย [[SUIT-015 O2 pti | *ย [[SUIT-015 O2 pti D043]] for permeabilized tissue | ||
ย | |||
{{Template:SUIT-015}} | {{Template:SUIT-015}} | ||
Line 33: | Line 24: | ||
:::+ FNS ET capacity is a good estimate of overall ET capacity in many cell types. | :::+ FNS ET capacity is a good estimate of overall ET capacity in many cell types. | ||
:::+ The presence of PMG and S establishes a fully operative TCA cycle activity. | :::+ The presence of PMG and S establishes a fully operative TCA cycle activity. | ||
:::+ Reasonable duration of the experiment. | :::+ Reasonable duration of the experiment. | ||
ย | :::- Application of the cytochrome ''c'' test after 3G in the protocol does not ensure comparability of all states in case of any effect of ''c''. However, it allows to analyse whether the outer mt-membrane integrity is compromised. | ||
:::- F OXPHOS capacity may be underestimated. In human heart muscle addition of Oct to palmitoylcarnitine (Pal) + malate increased OXPHOS by 26% ( | :::- F OXPHOS capacity may be underestimated. In human heart muscle addition of Oct to palmitoylcarnitine (Pal) + malate increased OXPHOS by 26% (Lemieux et al 2011). | ||
:::- SRot(E) may be underestimated if S is not saturating. ย | :::- SRot(E) may be underestimated if S is not saturating. ย | ||
:::- CIV activity is not measured, to save experimental time. | :::- CIV activity is not measured, to save experimental time. | ||
Line 44: | Line 34: | ||
::::* [[SUIT-002]] | ::::* [[SUIT-002]] | ||
::::* [[SUIT-019]] ย | ::::* [[SUIT-019]] ย | ||
::::* [[ | ::::* [[SUIT-028]] | ||
== References == | |||
{{#ask:[[Category:Publications]] [[Instrument and method::O2k-Protocol]] [[Additional label::SUIT-015]] | |||
|?Was published in year=Year | |||
|?Has title=Reference | |||
|?Mammal and model=Organism | |||
|?Tissue and cell=Tissue;cell | |||
|format=broadtable | |||
|limit=5000 | |||
|offset=0 | |||
|sort=Was published in year | |||
|order=descending | |||
}} | |||
{{MitoPedia concepts | {{MitoPedia concepts | ||
|mitopedia concept=MiP concept, SUIT protocol, Recommended | |mitopedia concept=MiP concept, SUIT protocol, Recommended |
Latest revision as of 15:21, 8 June 2020
Description
Abbreviation: F+G+P+S_OXPHOS+Rot_ET
Reference: A: F-pathway in LEAK state and OXPHOS state
- SUIT protocol pattern: 1OctM;2D;3G;4P;5S;6U:7Rot-
SUIT-015 gives information on F-pathway in LEAK state and OXPHOS state avoiding FAO overestimation in the presence of anaplerotic pathways. In addition, the pathway control of FN and FNS in OXPHOS state and of FNS and S in ET state can be evaluated. SUIT-015 can be extended with the CIV assay module.
Communicated by Doerrier C, Huete-Ortega M, Gnaiger E (last update 2019-06-05)
Specific SUIT protocols
- SUIT-015 O2 pti D043 for permeabilized tissue
Steps and respiratory states
Step | State | Pathway | Q-junction | Comment - Events (E) and Marks (M) |
---|---|---|---|---|
1OctM | OctML | F(N) | CETF | 1OctM
|
2D | OctMP | F(N) | CETF | 1OctM;2D
|
3G | OctGMP | FN | CETF&CI | 1OctM;2D;3G
|
3c | OctGMcP | FN | CETF&CI | 1OctM;2D;3G;3c
|
4P | OctPGMP | FN | CETF&CI | 1OctM;2D;3G;3c;4P
|
5S | OctPGMSP | FNS | CETF&CI&II | 1OctM;2D;3G;3c;4P;5S
|
6U | OctPGMSE | FNS | CETF&CI&II | 1OctM;2D;3G;3c;4P;5S;6U
|
7Rot | SE | S | CII | 1OctM;2D;3G;3c;4P;5S;6U;7Rot
|
8Ama | ROX | 1OctM;2D;3G;3c;4P;5S;6U;7Rot;8Ama
|
Step | Respiratory state | Pathway control | ET-Complex | Comment |
---|---|---|---|---|
## AsTm | AsTmE | CIV | CIV | |
## Azd | CHB |
- Bioblast links: SUIT protocols - >>>>>>> - Click on [Expand] or [Collapse] - >>>>>>>
- Coupling control
- Pathway control
- ยป Electron transfer pathway
- ยป Fatty acid oxidation pathway control state, F
- ยป NADH electron transfer-pathway state, N
- ยป Succinate pathway control state, S
- ยป NS-pathway control state, NS
- ยป Glycerophosphate pathway control state, Gp
- ยป Complex IV single step, CIV
- ยป Anaplerotic pathway control state
- Pathway control
- Main fuel substrates
- ยป Glutamate, G
- ยป Glycerophosphate, Gp
- ยป Malate, M
- ยป Octanoylcarnitine, Oct
- ยป Pyruvate, P
- ยป Succinate, S
- Main fuel substrates
- Glossary
Strengths and limitations
- + The protocol provides information on FAO capacity in the absence of other, potentially interfering pathways, both in the LEAK state and in OXPHOS.
- + FNS OXPHOS capacity comprises the most important pathways in many cell types and thus provides a physiologically relevant estimate of maximum mitochondrial respiratory capacity.
- + FNS ET capacity is a good estimate of overall ET capacity in many cell types.
- + The presence of PMG and S establishes a fully operative TCA cycle activity.
- + Reasonable duration of the experiment.
- - Application of the cytochrome c test after 3G in the protocol does not ensure comparability of all states in case of any effect of c. However, it allows to analyse whether the outer mt-membrane integrity is compromised.
- - F OXPHOS capacity may be underestimated. In human heart muscle addition of Oct to palmitoylcarnitine (Pal) + malate increased OXPHOS by 26% (Lemieux et al 2011).
- - SRot(E) may be underestimated if S is not saturating.
- - CIV activity is not measured, to save experimental time.
Compare SUIT protocols
References
MitoPedia concepts: MiP concept, SUIT protocol, Recommended
MitoPedia methods:
Respirometry